FDR's grandson discusses Social Security, Medicare go-broke dates being moved up
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Tennessee judge gives state leeway on deactivating inmate's heart-regulating device before execution
NASHVILLE, Tenn. (AP) — A Tennessee judge ruled on Tuesday that the state can deactivate a death-row inmate's implanted heart-regulating device at a hospital on the morning of his execution, rather than bringing a doctor or technician into the execution chamber. The ruling comes after Deputy Attorney General Cody Brandon told the judge they could not comply with an earlier order requiring Byron Black's implanted cardioverter-defibrillator to be turned off just prior to the injection of a lethal dose of pentobarbital on Aug. 5. In the Friday order, Davidson County Chancery Court Judge Russell Perkins agreed with Black's attorneys that not deactivating the device could cause Black to suffer needlessly as it continuously shocks him in an attempt to restore his heart's normal rhythm during the execution. At a Tuesday hearing on the issue, Brandon said Black's physicians at Nashville General Hospital are unwilling to come to the execution chamber. That means the Friday chancellor's order is, in effect, an order to stay the execution, which only the Tennessee Supreme Court has the power to do, he argued. Brandon asked the judge to either overturn his Friday order or allow the Tennessee Department of Correction to take Black to the hospital for the deactivation on Aug. 4. Kelley Henry, who represents Black, argued that the state should not be allowed to deactivate the device prematurely because doing so could result in Black's death while he still has the possibility of a last-minute reprieve. ' On August 4, we will still be in other courts seeking a stay of execution,' Henry said. She also said state officials had not really tried to find a doctor willing to come to the prison. She first brought the issue up with the Tennessee Department of Correction in early June, but it was not until the Friday order that they began to look into it, and then they only contacted Nashville General Hospital. 'It's like when you tell a teenager to clean up their room, and they pick up one sock,' she said. The implantable cardioverter-defibrillator is a small, battery-powered electronic instrument, surgically implanted in the chest, that serves as a pacemaker and an emergency defibrillator. Perkins noted in court on Tuesday that during a two-day hearing last week on the issue, a doctor testifying for Black said that deactivating the device is quick and doesn't require surgery, only a handheld machine. Meanwhile, the state did not present any testimony at the time that deactivation would be an administrative or logistical burden. In modifying his own order on Tuesday, Perkins wrote that it is obvious the state has 'taken only minimal steps' to comply with his Friday order. However, Perkins said he also wants to ensure that his ruling can't be construed as an attempt to interfere with the execution. 'I've lost sleep over this because I want to do the right thing,' Perkins said at the hearing. 'I want to honor the memories of these victims' while also making sure the execution is properly carried out. Black was convicted in the 1988 shooting deaths of girlfriend Angela Clay, 29, and her two daughters, Latoya, 9, and Lakeisha, 6. Prosecutors said Black was in a jealous rage when he shot the three at their home. At the time, Black was on work-release while serving time for shooting and wounding Clay's estranged husband. 'Had she not been killed, Lakeisha would be in her 40s today,' Brandon told the judge on Tuesday. 'Justice has waited 37 years. It should not wait any longer.' Black's motion related to his heart device came within a general challenge he and other death row inmates filed against the state's new execution protocol. The trial isn't until 2026.
Yahoo
25 minutes ago
- Yahoo
Astrana Health, Inc. Schedules 2025 Second Quarter Financial Results Release and Conference Call
ALHAMBRA, Calif., July 22, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the second quarter ended June 30, 2025, after the close of the stock market on Thursday, August 7, 2025. The Company will discuss those results on a conference call at 2:30 p.m. PT/5:30 p.m. ET that same day. Astrana Health Logo (PRNewsfoto/Astrana Health, Inc.) Participant Dial-in Numbers: 877-858-9810 / +1 201-689-8517 To access the call, please dial in approximately five minutes before start time. An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website ( after issuance of the earnings release. Webcast The call will also be available via online webcast at: Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call. About Astrana Health, Inc. Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system. Today, Astrana supports more than 20,000 providers and over 1.6 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together, Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit FOR MORE INFORMATION, PLEASE CONTACT: Grant Hesser, Investor Relations Cision View original content to download multimedia: SOURCE Astrana Health, Inc.
Medscape
26 minutes ago
- Medscape
Remembering Dr Atul Butte, a Medical Hero
'Like Mike. If I could be like Mike.' On August 8, 1991, Gatorade launched one of the most successful advertising campaigns in history. "Be Like Mike" featured children and adults of all backgrounds emulating basketball great Michael Jordan's moves while the famous jingle played: "Sometimes I dream / That he is me / You've got to see that's how I dream to be." (The rest will play in your head. You're welcome). The campaign tapped into our primal need for role models. Atul Butte, MD, PhD The ad's genius lay not in selling sugar water but in commodifying aspiration. Here was the divine Jordan, tongue out, defying gravity, and a simple message: You too can transcend earthly limitations. We all knew better. And yet, I had my own Mike-like space-creating move to a fadeaway that worked (once). I'm sure I pumped my fist like Mike when it dropped. Heroes like Jordan are harder to find in medicine, but we can still seek them out among the diagnostic savants, the surgical virtuosos, the masterful presenters. Dr Atul Butte, a pediatric endocrinologist turned data evangelist, was one of those heroes. Like with Jordan, I never met Dr Butte but knew him from afar. His talks were inspiring, not just for his comedic, down-to-earth style, but also for the work that they represented. Butte trained as a pediatric endocrinologist. Early in his career, he recognized that while we doctors generate massive amounts of data — from research, electronic medical records, genomics — we weren't making full use of it. Hidden in those gigabytes were insights that could improve diagnosis and treatment and prevent disease. So, Butte pivoted. He immersed himself in data science. He collaborated across disciplines. And he refused to let traditional career paths define him. Over time, he became a leader in computational health, founded multiple biotech startups, and directed informatics for all of the University of California Health Systems. His mission was to transform messy data into actionable knowledge that helps patients. What I find inspiring about Butte isn't just the scale of his success; it was his curiosity. His refusal to accept 'this is the way we do things.' His optimism. And his remarkable generosity. He was as enthusiastic about sharing as he was about discovering. The crush of conference goers would always be six deep to the dais when lights came up. There's something moving about this commitment to sharing knowledge and tools, especially in an era when information is hoarded as intellectual property. Butte's students — now scattered across universities and hospitals and technology companies — carry forward not just his methods but his approach to problems: curious, collaborative, persistently optimistic about the possibility of reducing human suffering through better understanding. Watching highlight reels of Dr Butte's career, we can see what separates the GOATs from the rest of us. He showed us that we should value connection as much as we value expertise. To see that in a world drowning in information, the ability to make meaningful connections across different domains of knowledge is essential for excellence. His core philosophy, summed up as "unfreezing" biomedical data, was a vision for the future of medicine. His genius was in asking simple, yet audacious questions: "What if we could spot patterns across millions of patients, not just the few in our own clinics?' This wasn't idle curiosity; it was a pragmatic, mischievous drive to build the teams and tools to make it happen. In one striking example, Butte's team analyzed data to discover that cimetidine showed promise in treating lung adenocarcinoma. Here was a drug sitting on shelves for decades and hidden there was something that might help patients with cancer. His virtuoso was to play effortlessly between medicine, computer science, and engineering. After his untimely death at the age of 55 in June, tributes to him poured into LinkedIn. Colleagues remembered him not just as a visionary, but as a "big bear of a man with a huge smile and love for everyone." He was described as having "energy that could power a room" and a unique ability to "elevate people around him." His advocacy and his dedication to mentoring "hundreds if not thousands" of students and researchers — making them feel supported and seen — speak volumes. He believed in "scalable privilege," that data insights should be accessible to all, and he lived that belief by empowering those around him. Dr Atul Butte showed us new, creative moves, and perhaps just as important, the same encouraging, radiant Jordan-like smile that made us believe we could actually play like him. By nurturing that curiosity — and channeling a bit of that infectious optimism — we can discover new tools and techniques to advance the practice of medicine. We should all wanna be like him. Jeffrey Benabio, MD, MBA, is chief of dermatology at Kaiser Permanente San Diego. The opinions expressed in this column are his own and do not represent those of Kaiser Permanente. Dr Benabio is @Dermdoc on X.
